VAXART (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?

Shares of VAXART, INC. (NASDAQ:VXRT - Get Free Report) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.54 and traded as low as $0.42. VAXART shares last traded at $0.44, with a volume of 3,607,483 shares changing hands.

Wall Street Analyst Weigh In

Several analysts have commented on VXRT shares. B. Riley dropped their target price on shares of VAXART from $2.50 to $2.00 and set a "buy" rating for the company in a research report on Thursday, March 27th. Wall Street Zen raised VAXART to a "hold" rating in a research note on Thursday, May 22nd.

VAXART Price Performance

The business's 50-day moving average is $0.47 and its two-hundred day moving average is $0.54.

VAXART (NASDAQ:VXRT - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $20.88 million during the quarter, compared to the consensus estimate of $2.85 million. VAXART had a negative net margin of 122.63% and a negative return on equity of 91.89%. Research analysts predict that VAXART, INC. will post -0.39 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Steven Lo purchased 100,000 shares of the business's stock in a transaction on Monday, May 19th. The shares were purchased at an average price of $0.49 per share, with a total value of $49,000.00. Following the completion of the purchase, the insider owned 100,000 shares in the company, valued at $49,000. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On VAXART

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. acquired a new position in shares of VAXART during the first quarter worth about $31,000. Jones Financial Companies Lllp boosted its position in VAXART by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after acquiring an additional 478,111 shares during the last quarter. Virtu Financial LLC bought a new position in shares of VAXART during the 1st quarter worth approximately $56,000. Invesco Ltd. raised its holdings in shares of VAXART by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 70,568 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of VAXART by 95.0% in the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock valued at $342,000 after purchasing an additional 251,789 shares during the last quarter. 18.05% of the stock is currently owned by institutional investors and hedge funds.

VAXART Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.